Organogenesis is a leading regenerative medicine brand that is dedicated to empowering healing through the development, manufacturing, and sale of products for the advanced wound care, surgical, and sports medicine markets. With a mission to provide an integrated portfolio of healing solutions that improve lives while reducing the overall cost of healthcare, Organogenesis is committed to continuously pursuing quality and innovation. In the field of advanced wound care, Organogenesis offers a comprehensive range of regenerative medicine products that are specifically designed for the treatment of chronic and acute wounds.

These products support patients throughout the entire wound healing process, from the initial stages to complete wound closure, regardless of the type of wound. Additionally, Organogenesis provides surgical and sports medicine products that aid in the healing of musculoskeletal injuries, including degenerative conditions like osteoarthritis and tendonitis. Established in 1985 as a spin-off of technology developed at MIT, Organogenesis has a long history of successful healing solutions.

They introduced the first FDA-approved living cell-based product, Apligraf®, which treats both diabetic foot ulcers and venous leg ulcers. Over the years, their product portfolio expanded to include other innovative solutions like Dermagraft® and the PuraPly® line. In 2017, Organogenesis acquired NuTech Medical, enabling them to further expand their product portfolio and venture into the surgical and sports medicine markets.

With major milestones including FDA approvals and the launch of new product lines, Organogenesis continues to be a force in the field of regenerative medicine. © 2023 Organogenesis Inc. All rights reserved.

Connect with us to learn more about their advanced wound care, surgical and sports medicine products and how they can provide solutions for patients, professionals, and the healthcare industry